Related Experiment Videos
F responses and central motor conduction in multiple sclerosis
1Department of Clinical Neurophysiology, National Hospital, Queen Square, London, U.K.
Electroencephalography and Clinical Neurophysiology
|November 1, 1989
Summary
Central motor conduction (CMC) is a better indicator of subclinical motor lesions in multiple sclerosis (MS) than F wave responses. Abnormal CMC was found in 36% of patients with normal clinical exams, compared to 23% with abnormal F responses.
Area of Science:
- Neuroscience
- Clinical Electrophysiology
Background:
- Multiple sclerosis (MS) is a demyelinating disease affecting the central nervous system.
- Electrophysiological investigations are crucial for assessing motor pathway integrity in MS.
Purpose of the Study:
- To compare the utility of F wave characteristics and cortical magnetic stimulation (CMS) for detecting motor pathway abnormalities in MS patients.
- To determine which electrophysiological test is more sensitive for identifying subclinical motor lesions in MS.
Main Methods:
- Studied 18 MS patients using two electrophysiological methods: F wave analysis (motoneurone excitability) and CMS (central motor pathway conduction).
- Assessed F wave amplitude, persistence, and frequency, alongside CMS-derived central motor conduction (CMC) parameters.
Main Results:
- Increased mean F wave amplitude and persistence were observed in patients with abnormal CMC and those with normal CMC but clinical upper motor neuron (UMN) signs.
- No significant correlation was found between the degree of CMC abnormality and F response changes, nor between specific F wave characteristics and clinical signs.
- Abnormal CMC detected subclinical motor lesions in 36% of clinically normal patient sides, whereas abnormal F responses were found in 23%.
Conclusions:
- Central motor conduction (CMC) appears more sensitive than F wave responses for detecting subclinical motor lesions in multiple sclerosis.
- Electrophysiological assessment, particularly CMC, aids in identifying motor pathway dysfunction even in the absence of overt clinical symptoms.